Gilead Sciences, Inc. GILD posted better-than-expected third-quarter 2025 results and lifted the lower end of its product ...

Gilead Sciences, Inc. (Nasdaq: GILD) today announced it has been awarded the prestigious 2025 Prix Galien USA Award for Best ...

Gilead has chosen a partner for lenacapavir in the race to develop new low-frequency treatments for HIV. | Gilead has chosen ...

Kenya's health ministry, through NASCOP, NSDCC, KRCS, county governments, partners and communities, is committed to ending ...

The plan underscores Kenya’s progressive approach to combination HIV prevention, offering a range of proven and emerging options including condoms, the dapivirine ring, long-acting injectable ...

South Africa has made history by becoming the first African nation to register Lenacapavir, a revolutionary long-acting ...

Gilead Sciences reports Q3 earnings Oct 30. Discover estimates, analyst revisions, and past performance stats.

The timing of the renewed support is pivotal. South Africa is preparing to roll out Lenacapavir, a groundbreaking long-acting antiretroviral treatment, as early as March or April 2026.

When President Donald Trump issued an executive order suspending all foreign aid to South Africa, in January this year, we immediately set about finding solutions. Among the most pressing was to ...

Gilead Sciences gears up for Q3 results with strong HIV gains and new FDA approvals, amid challenges in its Cell Therapy ...

South Africa approved lenacapavir on October 21, 2025—a twice-yearly injection offering near-100% HIV protection. This ...

SAHPRA has registered Lenacapavir, a new six-monthly PrEP injection to prevent HIV-1 in adults and adolescents over 35 kg.